RP2-Related Retinopathy: Comprehensive Disease Characteristics Report

1. Disease Information

Overview: RP2-related retinopathy (also termed RP2-associated X-linked retinitis pigmentosa) is a form of inherited retinal degeneration caused by hemizygous pathogenic variants in the RP2 gene on the X chromosome. It presents in males as a severe, early-onset, rapidly progressive rod-cone dystrophy, and in female carriers as a highly variable phenotype ranging from asymptomatic to RP-level vision loss due to X-inactivation (Lyonization). RP2 was the second gene identified as a cause of X-linked retinitis pigmentosa (XLRP), historically accounting for roughly 10–20% of XLRP cases (some sources cite up to 16–20%), with RPGR accounting for the majority (~60–75%) (PMC3124502, PMC5353642).

Key identifiers: - Gene/OMIM disease entry: RP2, OMIM #312600 (Retinitis Pigmentosa 2); gene locus OMIM 300757 (RP2 Activator of ARL3 GTPase) - Related OMIM entries: #268000 (Retinitis Pigmentosa, general); #300455 (X-linked RP and sinorespiratory infections ± deafness, RPSRDF — contiguous gene deletion syndrome involving RP2) - Gene location: Xp11.3 (5 exons, ~1,050 bp coding sequence, 350 amino acid protein) - Orphanet: ORPHA791 (Retinitis pigmentosa, umbrella term); a gene-specific Orphanet entry also exists for RP2-related XLRP - MONDO: MONDO:0100442 (RP2-related retinopathy, per task); umbrella RP term MONDO:0019200 - ICD-10: H35.52 (pigmentary retinal dystrophy), broader H35.5 - MeSH: Retinitis Pigmentosa (D012174) - Disease Ontology:* DOID:10584

Data source type: This report synthesizes aggregated disease-level literature — natural history cohort studies, case series, functional/molecular studies, and model organism data — rather than individual EHR-derived data.

2. Etiology

Disease causal factor: Purely genetic/monogenic. Hemizygous (males) or heterozygous (females, with variable expressivity) loss-of-function or dysfunction-causing variants in RP2 cause disease; no environmental or infectious cause is established.

Genetic risk factors: - Causal variants in RP2: nonsense, frameshift, splice-site, and missense variants, plus whole-gene/partial-gene deletions (PMC10190057; PMC9738434 natural history study found 5 nonsense, 6 frameshift, 1 splice-site, 1 missense among 24 variants in one cohort). - X-linked inheritance means male sex is itself a major risk determinant for full-penetrance disease. - Family history of X-linked disease — but per PMC11139645 (female carrier study), "family history of affected females with RP does not exclude X-linked disease," since carrier females can be symptomatic.

Environmental/lifestyle risk factors: None specifically established for RP2; as with RP broadly, no consistent environmental modifiers are documented in the reviewed literature.

Protective factors: No validated genetic or environmental protective factors specific to RP2 were identified in the literature searched. In female carriers, favorable (non-random) X-inactivation skewing toward the mutant allele functions as a protective factor at the individual level (PMC11139645): "The disease spectrum is likely explained by Lyonization, whereby random X-chromosome inactivation during embryogenesis leads to variable expression of the wild-type phenotype."

Gene-environment interactions: None specifically documented for RP2; vitamin A/E supplementation interactions are described for RP broadly (see Prevention/Treatment) but not RP2-specific.

Modifier genes: No validated modifier genes were reported; the natural history study (PMC9738434) explicitly found "no evidence of genotype–phenotype correlation" among variant types, and female carrier phenotype is modified primarily by X-inactivation pattern rather than a second gene.

3. Phenotypes

Male (hemizygous) patients — from natural history study of 47 males/33 families (PMC9738434, Ophthalmology 2022/2023, PMC10567581):

Age of onset: Median first symptoms at 7 years (IQR 2.25–12); median baseline exam age 20 years. Onset is childhood, distinctly earlier than typical autosomal RP.

Severity/progression: Rapid and progressive. - BCVA: median 0.66 logMAR at baseline → 1.3 logMAR at last visit; progression rate of 46–49% acuity loss per decade; legal blindness reached by a median age of 27 years. - Central retinal thickness declining 12.6–13.9% per decade; photoreceptor+RPE complex declining 27–33.9% per decade. - Ellipsoid zone intact in only 34.3% at baseline (median age 14.5y) vs. severely disrupted/atrophic in 65.7% (median age 35y); EZ becomes "largely not measurable from 25 years of age." - Overall course: "rapid progression to outer retina atrophy and early macular involvement with substantial vision loss by age 30–40."

High myopia is a recognized associated feature, and fundus appearance can mimic choroideremia (per PreventionGenetics/differential diagnosis literature) without choroideremia-gene involvement — an important diagnostic pitfall.

Female carriers — from cohort of 27 carriers/21 pedigrees (PMC11139645, AJO 2023/2024):

• 85% asymptomatic with normal vision; 15% with RP-level complaints
• Fundus: normal (30%), tapetal-like reflex/TLR (37%), scattered peripheral pigment (19%), overt RP changes (15%)
• Visual acuity (WHO criteria): no/mild impairment 89%, moderate 3.7%, blind 7.4%
• Full-field ERG abnormal in 82% (9/11 tested), often asymmetric
• Radial fundus autofluorescence pattern in virtually all TLR carriers
• Slowly progressive atrophic changes documented over 6.7–11.4 years in symptomatic carriers

Quality of life impact: No RP2-specific QOL study was found, but the broader XLRP burden literature (EXPLORE XLRP-2 study, PMC11794432, Eye 2025) is informative: among 169 XLRP patients (RPGR-predominant cohort), anxiety was reported by 74.2% and depression by 15.8%; severe disease correlated with difficulties in low-luminance function, employment, and mobility; mean diagnostic delay from symptom onset to genetic diagnosis was 16.4 years. These burden patterns are considered broadly applicable to RP2-XLRP given phenotypic overlap.

Suggested HPO terms: HP:0000546 (Retinal degeneration/atrophy), HP:0000662 (Nyctalopia), HP:0000639 (Nystagmus), HP:0007737 (Bone spicule pigmentation), HP:0007843 (Attenuation of retinal blood vessels), HP:0000543 (Optic disc pallor), HP:0000505 (Visual impairment), HP:0000545 (Myopia), HP:0000577 (Exotropia — if applicable), HP:0000512 (Abnormal electroretinogram).

4. Genetic/Molecular Information

Causal gene: RP2 (HGNC:10295), OMIM *300757, chromosome Xp11.3, NCBI Gene ID 6102. Encodes a 350-amino-acid, ubiquitously plasma-membrane/ciliary-localized protein.

Protein domain structure (UniProt O75695 / GeneCards): - N-terminal domain: homologous to tubulin-specific chaperone cofactor C (a β-helix domain involved in tubulin GTPase activation) - C-terminal domain: homology to nucleoside diphosphate kinases (NDK); "the physiological function of the NDK domain in RP2 remains to be determined" though it has also been reported to have 3'→5' exonuclease activity and nuclear translocation after DNA damage (ScienceDirect, S001448270500621X)

Variant classification/type (ClinVar, PMC9738434, PMC11139645): - Nonsense, frameshift, splice-site, missense, and whole/partial gene deletions - In the 47-male natural history cohort: 24 total variants (13 novel) — 5 nonsense, 6 frameshift, 1 splice-site, 1 missense (proportions approximate; most common: c.352C>T p.(Arg118Cys) and c.358C>T p.(Arg120)) - In the 21-pedigree carrier cohort: frameshift 28.6%, nonsense 28.6%, missense 23.8%, plus splice-site, whole-gene deletion, and smaller deletions - ClinVar: "39 ClinVar submitters have submitted clinical-significance assessments... after 2014, and all submitters classified the variants as pathogenic or likely pathogenic" — reflecting high consensus once a variant is curated, per ACMG/AMP framework - Up to 133 disease-associated variants* have been reported across the literature (PMC3124502)

Functional consequences: Frameshift/nonsense variants generally cause complete loss of function via truncation/nonsense-mediated decay; missense variants show variable pathogenic potential — some behave as near-null, others as partial hypomorphs (PMC3124502, "Functional Analysis of RP2 Protein Reveals Variable Pathogenic Potential of Disease-Associated Missense Variants"). Missense variants clustering in the ARL3-binding/N-terminal domain most consistently impair GAP activity; notably in the female carrier study, "no carriers with [ARL3-binding domain] variants were affected," while variants in the ferredoxin-like/β-helix domains were more often associated with an affected carrier phenotype — suggesting domain-specific severity even though no clear genotype-phenotype correlation was found in the male cohort.

Protein function/mechanism: RP2 acts as a GTPase-activating protein (GAP) for ARL3 (ADP-ribosylation factor-like 3), a small ciliary GTPase (Reactome R-HSA-5638007). RP2 stimulates GTP hydrolysis on ARL3-GTP, triggering release of UNC119(B)-bound lipidated cargo (e.g., transducin, NPHP3) at the ciliary base/membrane — a key step in selective ciliary protein trafficking.

Modifier genes: None validated; X-inactivation pattern (not a second gene) is the principal modifier of female carrier phenotype.

Epigenetic information: X-chromosome inactivation (Lyonization) is the central "epigenetic" determinant of phenotype expression in female carriers — this is not a disease-specific epigenetic mechanism but the generic mechanism underlying all X-linked carrier variability.

Chromosomal abnormalities: Contiguous gene deletions spanning RP2 and neighboring genes cause a distinct contiguous gene deletion syndrome, OMIM #300455 (X-linked RP with sinorespiratory infections ± deafness), illustrating that large deletions removing RP2 plus adjacent loci produce a syndromic phenotype beyond isolated retinopathy.

Suggested ontology terms: GO:0005096 (GTPase activator activity), GO:0060271 (cilium assembly), GO:0035861 (site of double-strand break — n/a), GO:0060170 (ciliary membrane), GO:0032391 (photoreceptor connecting cilium).

5. Environmental Information

No established environmental toxins, occupational exposures, or lifestyle factors are causally linked to RP2-related retinopathy — it is fully genetically determined. No infectious agents are implicated. (Not applicable beyond the general RP literature on vitamin A/E supplementation discussed under Treatment/Prevention.)

6. Mechanism / Pathophysiology

Causal chain: Pathogenic RP2 variant → loss/reduction of RP2 GAP activity toward ARL3 → failure of ARL3-GTP hydrolysis → impaired release of UNC119-bound lipidated cargo (transducin, and related proteins) at the photoreceptor connecting cilium → mistrafficking of phototransduction proteins into/through the outer segment → progressive photoreceptor dysfunction and death.

Molecular pathway specifics: - RP2-ARL3-UNC119 axis governs trafficking of lipidated proteins (e.g., farnesylated/prenylated cargo) across the connecting cilium (PMC5808637; Reactome R-HSA-5638007). - RP2/ARL3 also regulate trafficking of the ciliary tip kinesins KIF7 and KIF17, needed for intraflagellar transport (IFT)-related delivery to the cilium tip. - RP2 additionally supports Golgi cohesion and general vesicle trafficking/tubulin folding (via its cofactor-C-like domain), important for delivering opsins and other outer-segment cargo from the Golgi to the base of the connecting cilium.

Cellular processes: Impaired intracellular/intraciliary protein trafficking → progressive rod and cone photoreceptor degeneration via apoptosis; in RP2-knockout mouse and iPSC-organoid models, cone opsin (M-opsin) and rhodopsin mistrafficking, and diminished cone-specific GRK1 and PDE6 localization in outer segments, precede overt cell death.

Protein dysfunction: Predominantly loss of function (nonsense/frameshift/deletions) with some missense alleles causing partial or dominant-negative dysfunction of GAP activity (PMC3124502).

Tissue damage mechanism: Chronic photoreceptor-intrinsic ciliary trafficking failure leads to progressive apoptotic photoreceptor loss beginning with rods (nyctalopia) and extending to cones and RPE/outer retina (macular/central involvement), culminating in outer retinal atrophy.

Molecular profiling (model systems): - iPSC-derived retinal organoid transcriptomic/histologic data (Stem Cell Reports 2020, PMC7363745): CRISPR RP2-knockout and R120X patient-derived organoids show peak rod photoreceptor cell death around day 150 of culture and outer nuclear layer thinning by day 180; AAV-mediated RP2 gene augmentation rescued ONL thinning and restored rhodopsin expression. - Mouse knockout models show early cone dysfunction (mistrafficking of cone opsin, GRK1, PDE6) preceding degeneration, described as "early-onset cone dysfunction, followed by progressive cone degeneration, mimicking cone vision impairment in XLRP patients," though overall murine phenotype is milder than human disease.

Suggested GO/CL terms: GO:0007601 (visual perception), GO:0035845 (photoreceptor cell outer segment organization), GO:0006915 (apoptotic process), CL:0000210 (photoreceptor cell), CL:0000573 (retinal cone cell), CL:0000604 (retinal rod cell), CL:0000232 (retinal pigment epithelial cell — via GO:0032391 connecting cilium).

7. Anatomical Structures Affected

Organ level: Primary organ — the eye/retina (neurosensory retina, primarily photoreceptor layer; RPE secondarily). No consistent extra-ocular organ involvement in isolated RP2 disease, though contiguous-gene deletion cases (OMIM #300455) add sinorespiratory and hearing involvement (UBERON:0000949 endocrine — n/a; UBERON:0001004 respiratory system; UBERON:0001846 - middle ear structures for deafness).

Tissue/cell level: Rod photoreceptors (affected earliest — nyctalopia), cone photoreceptors (progressive involvement, central/macular vision loss), retinal pigment epithelium (atrophy with disease progression). Cell Ontology: CL:0000604 (rod), CL:0000573 (cone), CL:0002586 (retinal pigment epithelial cell).

Subcellular level: Connecting cilium / ciliary transition zone of photoreceptors (GO:0032391); Golgi apparatus (vesicle sorting, GO:0005794); outer segment membrane disc trafficking machinery.

Localization: Bilateral, generally symmetric in males; asymmetric/unilateral presentations reported in female carriers and rare male case reports (PMC10190057 — "asymmetric presentation with a novel RP2 gene mutation"). UBERON:0000966 (retina), UBERON:0001782 (macula lutea, for macular involvement).

8. Temporal Development

Onset: Pediatric/childhood — median age at first symptom 7 years in males; insidious onset of nyctalopia, sometimes with early nystagmus in infancy signaling more severe congenital-onset disease.

Progression: Rapid and relentlessly progressive (not episodic or relapsing-remitting). - Early stage (childhood–adolescence): nyctalopia, peripheral field constriction, intact ellipsoid zone in a minority - Intermediate stage (teens–20s): progressive EZ disruption, vessel attenuation, bone-spicule pigment - Advanced stage (30s–40s): outer retinal atrophy, macular involvement, legal blindness by median age 27 - Disease course pattern: chronic, lifelong, progressive (not self-limited); "46–49% BCVA loss per decade" quantifies the rate.

Patterns: No spontaneous remission described. In female carriers, disease can remain stable and mild for decades if X-inactivation favors the wild-type allele, or progress "slowly" (documented over 6.7–11.4 year follow-up) if unfavorably skewed. No defined "critical window" for intervention is established in the human literature, though preclinical gene-therapy rescue data (mouse, organoid) suggest earlier intervention (before extensive photoreceptor loss) yields better structural/functional rescue.

9. Inheritance and Population

Epidemiology: RP overall affects ~1/3,000–5,000; XLRP accounts for 5–15% of all RP and has a worldwide prevalence of roughly 1:30,000–1:40,000. Within XLRP, RPGR accounts for ~60–75% of cases and RP2 accounts for approximately 10–20% (estimates range 5–20% depending on cohort; PMC3124502, PMC5353642). No RP2-specific population prevalence figure was identified in the literature searched.

Inheritance pattern: X-linked — historically described as X-linked recessive, though the existence of a substantial fraction of symptomatic female carriers (documented above) means the disease is now often characterized as showing quasi-dominant or intermediate/semi-dominant inheritance with sex-limited penetrance modulated by X-inactivation, rather than "true" recessive inheritance.

Penetrance: Complete in hemizygous males; incomplete and variable in heterozygous females (only 15% symptomatic in the reviewed cohort), governed by random X-inactivation skewing.

Expressivity: Highly variable, especially in females (ranging from normal fundus to full RP); in males, expressivity is more uniform/severe, though the natural history study found no genotype-phenotype correlation across variant types.

Genetic anticipation: Not reported/not applicable (not a repeat-expansion disorder).

Germline mosaicism: Not specifically quantified in the reviewed literature for RP2, though it is a general consideration in X-linked disorder genetic counseling.

Founder effects/geographic distribution: No major founder mutations for RP2 were identified in the searched literature (contrast with RPGR ORF15 mutational hotspot, which accounts for ~2/3 of RPGR disease alleles). RP2 variants are described as diverse and largely private/family-specific across cohorts (Chinese, European/US cohorts referenced).

Consanguinity role: Not a significant factor given X-linked (not autosomal recessive) inheritance.

Carrier frequency: Not specifically reported; inferred to be very low given rarity of RP2 pathogenic alleles (private variants predominating over founder alleles).

Sex ratio: Disease manifests fully in males; females are carriers with variable, generally milder or absent phenotype — consistent with the essentially exclusive-male full phenotype pattern of X-linked RP.

Age distribution: Concentrated diagnosis in childhood-to-young-adult males (median baseline age in cohort 20 years); carrier females identified across a broad age range (16–76 years in the reviewed cohort) since many are ascertained through family cascade testing rather than symptoms.

10. Diagnostics

Clinical tests: - Fundus examination/fundus photography: bone-spicule pigmentation, vessel attenuation, waxy disc pallor - Fundus autofluorescence (FAF): hyperautofluorescent ring (parafoveal), radial pattern in carriers, progressive loss of AF signal - Optical coherence tomography (OCT/SD-OCT): ellipsoid zone (EZ) width/loss, central retinal thickness, photoreceptor+RPE complex thickness — all quantified with defined decline rates in the natural history study - Full-field electroretinography (ff-ERG): rod-cone dysfunction pattern, often severely reduced/non-recordable in advanced male disease; abnormal in 82% of tested carriers - Pattern ERG (PERG): used to detect macular dysfunction in carriers - Visual field testing: documents peripheral constriction - Visual acuity (BCVA, logMAR): primary functional endpoint tracked longitudinally

Genetic testing: - Single-gene RP2 sequencing or targeted XLRP gene panels (RP2 + RPGR ORF15 + OFD1, ± broader IRD panels) are the standard approach given clinical overlap - Whole exome/genome sequencing used when panel testing is non-diagnostic or phenotype is atypical - Chromosomal microarray: relevant when contiguous gene deletion (OMIM #300455) is suspected (e.g., syndromic features — deafness, recurrent sinorespiratory infection) - Sanger confirmation and segregation analysis in relatives remains standard for variant classification - No mitochondrial, repeat-expansion, or karyotype-specific testing is routinely indicated for isolated RP2 disease

Clinical criteria/differential diagnosis: Diagnosis relies on typical RP fundus/ERG findings plus X-linked pedigree pattern and confirmed hemizygous RP2 variant. Key differentials: RPGR-associated XLRP (most common XLRP gene; ORF15 mutational hotspot), choroideremia (RP2 disease can closely mimic choroideremia fundus appearance without CHM involvement — an important diagnostic pitfall noted in PreventionGenetics literature), autosomal RP forms, and other syndromic ciliopathies given RP2's ciliary function.

Screening: No population newborn screening; family cascade genetic testing/counseling is the main "screening" modality for at-risk relatives (particularly potential female carriers, given the significant proportion who are symptomatic).

11. Outcome/Prognosis

Visual prognosis (not life-threatening — an isolated ocular disease): - Legal blindness reached at a median age of 27 years in the male cohort - BCVA loss of ~46–49% per decade; substantial vision loss by age 30–40 - Structural retinal decline (EZ, CRT, PR+RPE thickness) parallels functional loss, with EZ becoming unmeasurable from age 25 onward in many patients — indicating this as a useful structural endpoint for future trials - Carrier females: prognosis is bimodal — majority retain good vision lifelong; a minority (~15% symptomatic, up to 7.4% legally blind in the reviewed cohort) progress to significant visual impairment

Morbidity/QOL: Drawing on the broader XLRP burden literature (EXPLORE XLRP-2), patients with severe disease show substantially higher rates of anxiety (74.2%), depression (15.8%), and impaired mobility/employment/daily functioning; diagnostic delay averages 16.4 years from symptom onset, a modifiable systemic factor affecting timely counseling and trial eligibility.

Complications: Cystoid macular edema and cataract can complicate advanced RP generally (not RP2-specific data identified); high myopia is a recognized associated ocular feature.

Prognostic factors: Earlier nystagmus at presentation may signal more severe/congenital-onset disease; no genotype-phenotype correlation has been established for variant type/location predicting severity in males. In females, X-inactivation skewing is the dominant prognostic determinant.

12. Treatment

Pharmacotherapy: No approved disease-modifying drug specific to RP2. General RP literature suggests vitamin A palmitate supplementation may modestly slow progression in some RP forms (evidence is weak/"insubstantial"), while high-dose vitamin E should be avoided (documented adverse effect on RP progression in the DHOM/Berson-type trials). No RP2-specific pharmacogenomic data exists.

Gene therapy (most promising avenue, preclinical/early translational stage): - AAV8/AAV9-mediated RP2 gene augmentation (full-length human RP2 coding sequence) has shown efficacy in RP2-knockout mouse models, achieving "long-term rescue of cone photoreceptor degeneration" (PMC4626763) and in iPSC-derived retinal organoids (isogenic RP2-knockout and R120X patient-derived), where AAV-RP2 "rescued the degeneration phenotype... preventing outer nuclear layer thinning and restoring rhodopsin expression" (Stem Cell Reports 2020, PMC7363745). - As of the literature reviewed, no RP2-specific gene therapy has yet reached registered human clinical trials (unlike RPGR, for which AGTC-501/laruparetigene zosaparvovec and 4D-125 are in Phase 1/2/3 trials, NCT04850118 and NCT04517149). RP2 vectors have been described as advancing toward clinical stage (NIH Tech Transfer listing) but a registered NCT trial specific to RP2 was not identified in this search.

Surgical/interventional: Argus II retinal prosthesis (FDA-approved for severe-to-profound RP of any genetic cause, age >25) is applicable to end-stage RP2 disease as a vision-restoration option, delivering electrical stimulation to surviving retinal cells via an epiretinal electrode array.

Supportive/rehabilitative: Low-vision aids, portable/adaptive lighting, orientation and mobility training, and genetic counseling are mainstays of current management.

Experimental: Retinal organoid and AAV vector platforms remain the primary experimental therapeutic pipeline; no RNA-based (ASO/siRNA) or small-molecule targeted therapy for RP2 was identified.

Suggested MAXO terms: MAXO term for "gene replacement therapy" (AAV-mediated gene augmentation), "retinal prosthesis implantation" (Argus II), "low vision rehabilitation," "genetic counseling," "dietary supplementation" (vitamin A).

13. Prevention

Primary prevention: Not applicable in the traditional sense (monogenic disease); genetic counseling and carrier testing for at-risk female relatives is the principal preventive strategy, given that carrier detection informs reproductive decision-making.

Secondary prevention/screening: Cascade genetic testing in families with a known RP2 variant; given that ~15% of female carriers are symptomatic, comprehensive ophthalmologic and genetic evaluation of at-risk females (not just male relatives) is recommended.

Reproductive options: Prenatal testing and preimplantation genetic diagnosis (PGD) are available options for known carrier families, following standard X-linked disorder genetic counseling frameworks (ACMG/NSGC), though no RP2-specific PGD outcome data was identified.

Tertiary prevention: Regular monitoring (OCT, FAF, ERG) to time low-vision intervention and clinical trial eligibility; avoidance of vitamin E supplementation; UV/blue-light protection is commonly recommended in general RP care (photoreceptor stress reduction), though direct RP2 evidence is lacking.

14. Other Species / Natural Disease

Taxonomy: Mus musculus (NCBI Taxon 10090) — Rp2-knockout mouse models exist; Danio rerio (NCBI Taxon 7955) — TALEN-generated rp2 knockout zebrafish.

Canine models — clarification: Initial search results returned OMIA:001518-9615 ("X-linked progressive retinal atrophy, type 2," XLPRA2) which is actually caused by RPGR ORF15 mutations, not RP2 — this is an important distinction to avoid conflating the two XLRP genes. No well-characterized naturally-occurring canine ortholog model specific to RP2 was identified in this search; canine XLPRA1/XLPRA2 remain the standard dog models for XLRP generally (via RPGR) and are useful comparators given similarities in ciliary photoreceptor biology.

Gene orthologs: Mouse Rp2 (MGI ortholog of human RP2), zebrafish rp2.

Comparative biology: Rp2-knockout mice show a milder phenotype than human disease — early cone-specific opsin/GRK1/PDE6 mistrafficking (as early as 2 months in one model, with ONL thinning by 5 months; another model showed abnormalities only by 14 months) followed by slow degeneration, useful for mechanistic study and therapy testing but not fully recapitulating the rapid, severe human course. Zebrafish rp2 knockouts show mild visual impairment (30% reduction in scotopic ERG b-wave) at 7 days post-fertilization. iPSC-derived retinal organoids (human, isogenic knockout and patient-derived) more directly recapitulate rod-predominant degeneration with defined kinetics (peak cell death ~day 150, ONL thinning by day 180) and have been used successfully for AAV rescue proof-of-concept.

Transmission/zoonotic potential: Not applicable (non-infectious genetic disease).

15. Model Organisms Summary

Summary of Key Data Gaps

• No RP2-specific prevalence/incidence figures (only pooled XLRP figures) were located.
• No RP2-specific registered human gene therapy trial (NCT number) was found — this differentiates RP2 from RPGR, where multiple trials are active/completed.
• No validated modifier genes or founder variants specific to RP2 were identified.
• No RP2-specific naturally-occurring large-animal (canine) model was identified — existing canine XLPRA models are RPGR-linked, not RP2-linked.

Sources

• Functional Analysis of RP2 Protein Reveals Variable Pathogenic Potential of Disease-Associated Missense Variants (PMC3124502)
• Asymmetric presentation with a novel RP2 gene mutation (PMC10190057)
• A Natural History Study of RP2-Related Retinopathy (PMC9738434)
• OMIM #268000 Retinitis Pigmentosa
• Analysis of RP2 and RPGR Mutations in Five X-Linked Chinese Families (PMC5353642)
• A Clinical Trial of Retinal Gene Therapy Using BIIB112 (NCT03116113 protocol)
• OMIM #300455 RPSRDF
• OMIM #312600 Retinitis Pigmentosa 2
• MalaCards Retinitis Pigmentosa
• ICD-10 H35.52 Pigmentary retinal dystrophy
• GeneCards RP2
• OMIM *300757 RP2 Activator of ARL3 GTPase
• Arl3 and RP2 regulate trafficking of ciliary tip kinesins (PMC5808637)
• Reactome: RP2 activates GTPase activity of ARL3
• RP2-Associated X-linked Retinopathy: Natural History in Female Carriers (PMC11139645)
• RP2 X-linked RP carrier state with vascular leakage (PMC10448798)
• RP2-Associated X-linked Retinopathy (PMC10567581)
• Moran CORE: RP2-Associated Retinitis Pigmentosa
• Long-term rescue of cone photoreceptor degeneration in RP2-KO mice (PMC4626763)
• Modeling and Rescue of RP2 RP Using iPSC-Derived Retinal Organoids (PMC7363745)
• RP2 Gene Analysis in X-Linked RP (GeneDx)
• The burden of XLRP on patient experience (EXPLORE XLRP-2, PMC11794432)
• OMIA:001518-9615 XLPRA2 (RPGR, not RP2 — noted correction)
• A putative silencer variant in a spontaneous canine model of RP (PLOS Genetics)
• Solution Structure of N-Terminal Domain of Tubulin Binding Cofactor C (PMC3196536)
• The RP2 protein exhibits exonuclease activity (ScienceDirect)
• AGTC-501 HORIZON Phase 1/2 24-month results (AJO)
• 4D-125 in Patients With XLRP (NCT04517149)

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: RP2-Related Retinopathy
• MONDO ID: (if available)
• Category: Mendelian

Research Objectives

Please provide a comprehensive research report on RP2-Related Retinopathy covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

RP2-Related Retinopathy (RP2-associated X-linked retinitis pigmentosa): Disease characteristics research report

Executive summary

RP2-related retinopathy is a severe, early-onset X-linked inherited retinal degeneration most commonly categorized clinically as X-linked retinitis pigmentosa (XLRP) / Retinitis Pigmentosa 2. RP2 encodes an ARL3 GTPase-activating protein (GAP) critical for ciliary/outer-segment trafficking of lipidated phototransduction proteins; disruption leads to progressive photoreceptor dysfunction and degeneration. There is no approved disease-modifying treatment in the retrieved evidence; management is supportive, while gene augmentation is supported by preclinical animal and human retinal organoid rescue studies. A dedicated global patient registry (InsightRP2; NCT06982417) has been launched to enable natural history and genotype–phenotype work to de-risk future RP2-directed trials. (birch2023overcomingthechallenges pages 1-2, pechnikova2025preclinicalandclinical pages 4-6, NCT06982417 chunk 1)

A compact, evidence-bounded table of key facts is provided below.

Table: This table condenses the most decision-relevant facts on RP2-related retinopathy from the retrieved evidence, including identifiers, phenotype, mechanism, diagnostics, prognosis, and the current translational landscape. It is designed for direct use in a disease knowledge base without adding unsupported identifiers or claims.

1. Disease information

1.1 Definition and overview

RP2-related retinopathy refers to retinal degeneration caused by pathogenic variation in RP2, typically presenting as RP2-associated XLRP with progressive loss of photoreceptor function and vision. Clinical manifestations commonly include night blindness, peripheral vision loss, and reduced visual acuity, usually with childhood onset and progression to severe impairment by early adulthood. (pechnikova2025preclinicalandclinical pages 4-6)

1.2 Key identifiers and controlled vocabulary

From ClinicalTrials.gov (InsightRP2 registry), the controlled vocabulary terms include: - MeSH: Retinitis Pigmentosa 2 (C567523); Retinitis Pigmentosa (D012174) (NCT06982417 chunk 1) - Broader MeSH ancestors relevant for classification: Eye Diseases, Hereditary (D015785), Retinal Dystrophies (D058499), Retinal Degeneration (D012162), Retinal Diseases (D012164), Genetic Diseases, Inborn (D030342) (NCT06982417 chunk 1)

OMIM/Orphanet/ICD-10/ICD-11/MONDO identifiers were not present in the retrieved corpus for this run; therefore they are not asserted here. (NCT06982417 chunk 1)

1.3 Synonyms / alternative names

• RP2-associated Retinitis Pigmentosa
• Retinitis Pigmentosa 2
• X-Linked Retinitis Pigmentosa (XLRP) (NCT06982417 chunk 1)

1.4 Evidence source type

The content in this report is derived from: - Aggregated disease-level and trial-design resources (expert panel proceedings; ClinicalTrials.gov registry) (birch2023overcomingthechallenges pages 1-2, NCT06982417 chunk 1) - Human cohort/clinic-based studies in inherited retinal disease, including pediatric cohorts that include RP2 cases (priglinger2024phenotypicandgenetic pages 10-11, priglinger2024phenotypicandgenetic pages 1-2) - Mechanistic reviews (photoreceptor trafficking) (frederick2020diffuseorhitch pages 7-10, frederick2020diffuseorhitch pages 10-13) - Model-organism and preclinical summaries (zebrafish; preclinical gene augmentation; organoids) (iribarne2020zebrafishphotoreceptordegeneration pages 6-8, noel2021zebrafishmodelsof pages 10-12, pechnikova2025preclinicalandclinical pages 14-16)

2. Etiology

2.1 Disease causal factors

Primary cause: germline pathogenic variants in RP2 causing X-linked inherited retinal degeneration (XLRP). (pechnikova2025preclinicalandclinical pages 4-6)

Contribution among XLRP genes: RP2 variants account for approximately 5–20% of XLRP, compared with RPGR accounting for ~60–80%. (pechnikova2025preclinicalandclinical pages 4-6)

2.2 Risk factors

• Genetic: having a pathogenic RP2 variant; sex-specific effects consistent with X-linked inheritance (males typically more severely affected; carrier females may manifest variably, but detailed carrier natural history was not retrievable in this run). (pechnikova2025preclinicalandclinical pages 4-6, birch2023overcomingthechallenges pages 6-8)
• Environmental: no RP2-specific environmental risk factors were identified in the retrieved evidence.

2.3 Protective factors

No RP2-specific protective genetic or environmental factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

No RP2-specific gene–environment interactions were identified in the retrieved evidence.

3. Phenotypes

3.1 Core phenotype spectrum (human)

Across the retrieved evidence, RP2-associated XLRP is characterized by: - Night blindness (nyctalopia) (symptom) (pechnikova2025preclinicalandclinical pages 4-6) - Peripheral vision loss / visual field constriction (symptom/sign) (pechnikova2025preclinicalandclinical pages 4-6) - Reduced visual acuity (symptom/sign) (pechnikova2025preclinicalandclinical pages 4-6) - High myopia and/or nystagmus as early referral features in young children in an IRD clinic cohort, with nyctalopia emerging later (priglinger2024phenotypicandgenetic pages 10-11)

Quantitative cohort observations (pediatric IRD cohort including RP2): - In one pediatric cohort, X-linked RP patients experienced night blindness at a median age of 16 years (X-linked RP overall). (priglinger2024phenotypicandgenetic pages 10-11) - For RP2 cases in that cohort, night blindness was described as a “cardinal and restricting symptom” in juveniles; 81% were myopic and described as having severe night blindness. (priglinger2024phenotypicandgenetic pages 10-11) - Rod–cone dystrophies (including RP2) could be subjectively asymptomatic at the time of genetic diagnosis in children, consistent with presymptomatic detection in screened settings. (priglinger2024phenotypicandgenetic pages 1-2)

3.2 Phenotype characteristics

• Onset: often childhood (pechnikova2025preclinicalandclinical pages 4-6)
• Progression: progressive; can become severe by early adulthood (pechnikova2025preclinicalandclinical pages 4-6)
• Severity/variability: severity varies among individuals; genotype–phenotype correlations are not clearly established in the retrieved sources. (pechnikova2025preclinicalandclinical pages 4-6)

3.3 Quality-of-life impact

Direct RP2-specific quality-of-life instruments (e.g., EQ-5D, VFQ-25) were not found in the retrieved evidence. Nevertheless, XLRP is described as progressing to legal blindness and blindness, implying major functional impacts. (pechnikova2025preclinicalandclinical pages 1-2)

3.4 Suggested HPO terms (mapping based on retrieved descriptions)

• Nyctalopia — HP:0000662
• Visual field constriction — HP:0001133
• Reduced visual acuity — HP:0007663
• High myopia — HP:0000545
• Nystagmus — HP:0000639

(These HPO identifiers are standard ontology mappings; the phenotypic claims are evidence-supported as cited above.) (pechnikova2025preclinicalandclinical pages 4-6, priglinger2024phenotypicandgenetic pages 10-11)

4. Genetic / molecular information

4.1 Causal gene

• RP2 (retinitis pigmentosa 2); locus reported as Xp11.23. (pechnikova2025preclinicalandclinical pages 4-6)

4.2 Functional role and molecular consequences

Current understanding (mechanism): - RP2 is a GTPase-activating protein (GAP) for ARL3, and functions with UNC119 and PDEδ in trafficking lipidated proteins (e.g., transducin, GRK1, PDE6) into the photoreceptor outer segment; this process is essential for phototransduction. (pechnikova2025preclinicalandclinical pages 4-6) - Mechanistically, RP2 accelerates ARL3-GTP hydrolysis, which is important for recycling PDEδ and completing prenylated-protein transport cycles; when this system fails, lipidated proteins can accumulate in inappropriate photoreceptor compartments rather than being delivered to the outer segment. (frederick2020diffuseorhitch pages 7-10) - RP2 also has structural similarity to cofactor C involved in β-tubulin folding and is linked to microtubule network biology, suggesting potential cytoskeletal contributions to disease pathogenesis. (pechnikova2025preclinicalandclinical pages 4-6)

Ontology suggestions (examples): - GO biological process: protein targeting to cilium, photoreceptor outer segment organization, intraciliary transport (supported conceptually by the trafficking pathway evidence) (pechnikova2025preclinicalandclinical pages 4-6, frederick2020diffuseorhitch pages 10-13) - GO cellular component: basal body, cilium, photoreceptor outer segment (pechnikova2025preclinicalandclinical pages 4-6)

4.3 Pathogenic variant spectrum / allele frequencies

Variant-class distributions, specific recurrent variants, and population allele frequencies (gnomAD) for RP2 were not available in the retrieved evidence set for this run. The evidence does note uncertainty/lack of clear genotype–phenotype correlations for RP2. (pechnikova2025preclinicalandclinical pages 4-6)

4.4 Modifier genes / epigenetics / chromosomal abnormalities

No RP2-specific modifier genes, epigenetic signatures, or chromosomal abnormality patterns were identified in the retrieved evidence.

5. Environmental information

No RP2-specific environmental or lifestyle contributors were identified in the retrieved evidence. This is consistent with RP2-related retinopathy being primarily a Mendelian genetic condition. (pechnikova2025preclinicalandclinical pages 4-6)

6. Mechanism / pathophysiology

6.1 Causal chain (conceptual)

1. Pathogenic RP2 variant → reduced/altered RP2 GAP activity for ARL3 and/or altered subcellular localization (pechnikova2025preclinicalandclinical pages 4-6)
2. Disrupted ARL3-GTP/GDP cycling and impaired cargo unloading/recycling (PDEδ/UNC119 pathways) (frederick2020diffuseorhitch pages 7-10, frederick2020diffuseorhitch pages 10-13)
3. Mislocalization and depletion of lipidated phototransduction proteins needed in outer segments (e.g., GRK1, transducin subunits) → photoreceptor functional defects (supported by zebrafish and mechanistic descriptions) (iribarne2020zebrafishphotoreceptordegeneration pages 6-8, frederick2020diffuseorhitch pages 7-10)
4. Progressive photoreceptor degeneration (rod followed by cone involvement in model systems) → clinical nyctalopia, peripheral field loss, reduced acuity, and eventual blindness (iribarne2020zebrafishphotoreceptordegeneration pages 6-8, pechnikova2025preclinicalandclinical pages 4-6)

6.2 Cell types (CL suggestions)

• Photoreceptor cell (rod photoreceptor; cone photoreceptor)
• Retinal pigment epithelium is relevant in general RP diagnostic studies but RP2 mechanism evidence here centers on photoreceptors/cilia (pechnikova2025preclinicalandclinical pages 4-6, iribarne2020zebrafishphotoreceptordegeneration pages 6-8)

7. Anatomical structures affected

7.1 Organ / tissue / cell level

• Primary organ: eye (retina), specifically photoreceptor layer and outer retina (by mechanism and RP phenotypes). (pechnikova2025preclinicalandclinical pages 4-6)

UBERON suggestions: - Retina — UBERON:0000966 - Photoreceptor layer — UBERON:0001880 (ontology suggestion)

7.2 Subcellular localization

• Evidence places RP2 in proximity to basal body/centriole at the photoreceptor base and in pathways controlling ciliary trafficking. (pechnikova2025preclinicalandclinical pages 4-6, frederick2020diffuseorhitch pages 10-13)

8. Temporal development

8.1 Onset

• Typical onset is childhood for RP2-associated XLRP, with some children presenting initially with high myopia and/or nystagmus and later developing prominent nyctalopia. (pechnikova2025preclinicalandclinical pages 4-6, priglinger2024phenotypicandgenetic pages 10-11)

8.2 Progression

• Progressive course, with severe impairment by early adulthood in RP2-associated disease (pechnikova2025preclinicalandclinical pages 4-6)
• For XLRP more broadly: substantial risk of blindness by age 40 in cohort data (see Prognosis). (birch2023overcomingthechallenges pages 2-4)

9. Inheritance and population

9.1 Inheritance pattern

• X-linked inheritance (XLRP) due to RP2 pathogenic variants. (pechnikova2025preclinicalandclinical pages 4-6)

9.2 Epidemiology (RP and XLRP context)

Because RP2-specific prevalence was not available in retrieved evidence, the best-supported estimates are for RP/XLRP: - RP prevalence reported as ~1:3700 to 1:8300 worldwide; XLRP represents ~10–20% of RP in one expert-panel summary. (birch2023overcomingthechallenges pages 2-4) - Another clinical study reports RP prevalence 1:3000–1:4000 and estimates ~2.5 million affected worldwide; inheritance breakdown: AR 50–60%, AD 30–40%, X-linked 5–15%. (savastano2024retinalpigmentepithelium pages 1-2)

9.3 Population genetics (carrier frequency; founder variants)

Not retrievable for RP2 specifically in this run.

10. Diagnostics

10.1 Clinical tests (typical IRD/RP workup)

Across modern RP/IRD studies, the diagnostic workup commonly includes: - Full-field ERG (functional staging) (savastano2024retinalpigmentepithelium pages 1-2, areblom2023adescriptionof pages 1-2) - Visual fields/perimetry (including Goldmann) (areblom2023adescriptionof pages 1-2) - OCT / SD-OCT ± FAF and multimodal fundus imaging (suleman2025currentunderstandingon pages 5-6, lynn2024expandingthemutation pages 1-2) - OCT angiography (OCTA) in some studies (savastano2024retinalpigmentepithelium pages 1-2)

A 2024 RP biomarker study incorporated visual field testing, full-field ERG, and OCTA as part of prospective evaluation. (savastano2024retinalpigmentepithelium pages 1-2)

10.2 Genetic testing approaches

• Comprehensive NGS gene panels are widely used, with pathogenicity classification per ACMG guidelines; one reinvestigation study used a 322-gene IRD panel and reported that repeated DNA testing improved genotype–phenotype understanding and potential eligibility for gene-based therapies. (areblom2023adescriptionof pages 1-2)
• In a US clinic-based 2022–2024 cohort, panel-based sequencing (Blueprint Genetics) was paired with standard imaging (SD-OCT; fundus photography) as real-world implementation of IRD diagnostics. (lynn2024expandingthemutation pages 1-2)

RP2-specific differential advice (pediatric cohort): in young patients with high myopia and ERG anomalies, clinicians should exclude RP2 (as well as CACNA1F and RPGR) even if night blindness is absent, reflecting age-dependent symptom reporting and phenotypic overlap among X-linked IRDs. (priglinger2024phenotypicandgenetic pages 10-11)

10.3 Differential diagnosis

Key alternative genetic diagnoses within X-linked IRD include RPGR (major XLRP gene) and CACNA1F/CHM depending on phenotype; distinguishing relies on combined phenotype, ERG patterns, and genetics. (priglinger2024phenotypicandgenetic pages 10-11, pechnikova2025preclinicalandclinical pages 4-6)

11. Outcome / prognosis

11.1 Prognosis (XLRP context)

• In one expert summary, by age 40 ~20% of XLRP individuals were blind, underscoring severity of X-linked disease. (birch2023overcomingthechallenges pages 2-4)
• Another XLRP review reports legal blindness median age ~45 years and that complete blindness typically occurs by ages 40–50 years (XLRP overall, not RP2-only). (pechnikova2025preclinicalandclinical pages 1-2)
• A clinical RP study reported average visual field loss 4–12% per year (RP overall, with X-linked described as worst prognosis). (savastano2024retinalpigmentepithelium pages 1-2)

11.2 RP2-specific outcomes

RP2-specific survival/mortality is not applicable (ocular disease). RP2-specific longitudinal visual function slopes were not retrievable in this run.

12. Treatment

12.1 Current standard management (supportive care)

The retrieved evidence emphasizes that XLRP has no approved treatment and management is largely supportive/symptomatic: - Visual aids; vitamin supplementation (does not halt progression) (pechnikova2025preclinicalandclinical pages 1-2) - Management of complications such as cystoid macular edema and cataracts using intravitreal anti-VEGF agents, corticosteroids, and cataract surgery (pechnikova2025preclinicalandclinical pages 6-9) - Retinal prosthetics (e.g., Argus II) with limited functional benefit (pechnikova2025preclinicalandclinical pages 6-9)

MAXO suggestions (examples): low-vision rehabilitation; cataract extraction; intravitreal anti-VEGF therapy; intravitreal corticosteroid therapy; genetic counseling.

12.2 Experimental / advanced therapeutics (RP2 relevant)

Gene augmentation for RP2 is supported in preclinical summaries: - Self-complementary AAV8-RP2 in mouse models: preservation of cone function over prolonged follow-up with toxicity at high doses reported. (pechnikova2025preclinicalandclinical pages 14-16) - Human retinal organoid models derived from RP2-knockout iPSCs showed rod degeneration by day ~150 and ONL thinning by day ~180, and AAV-RP2 gene augmentation rescued degeneration and restored rhodopsin expression. (pechnikova2025preclinicalandclinical pages 14-16)

12.3 Clinical development expert opinions (authoritative)

An expert panel on XLRP therapy development recommended: - Robust genetic screening to define eligible populations - Age stratification and emphasis on early natural history studies - Use of clinically meaningful functional and structural endpoints, with regulator engagement to validate endpoints (birch2023overcomingthechallenges pages 1-2, birch2023overcomingthechallenges pages 6-8)

These recommendations were framed around RPGR trials but explicitly acknowledge RP2 as a major XLRP cause. (birch2023overcomingthechallenges pages 1-2)

12.4 Clinical trials and real-world implementations

• InsightRP2 Registry (NCT06982417): recruiting observational cohort; aims to collect medical, genetic, and imaging data to enable natural history and genotype–phenotype research, with explicit goal to support gene therapy research. Start date 2025-05-01; outcomes include genotype–phenotype correlations in age of onset and progression. URL: https://clinicaltrials.gov/study/NCT06982417 (NCT06982417 chunk 1)
• Vitamin A supplementation pilot (NCT00065455): non-randomized study in RP (not RP2-specific) assessing acute ERG changes with high-dose vitamin A; ran Jul 2003–May 2009. URL: https://clinicaltrials.gov/study/NCT00065455 (NCT00065455 chunk 1)

13. Prevention

13.1 Primary prevention

No established primary prevention exists for RP2-related retinopathy (genetic). The prevention-relevant actions emphasized in the retrieved evidence are genetic and early-detection oriented: - Early ophthalmic screening visits in childhood may enable presymptomatic identification of IRDs. (priglinger2024phenotypicandgenetic pages 1-2)

13.2 Secondary/tertiary prevention

• Genetic counseling and family member testing are discussed in the pediatric IRD context, with attention to ethical constraints on predictive testing in minors in some jurisdictions. (priglinger2024phenotypicandgenetic pages 16-17)

14. Other species / natural disease

No naturally occurring RP2 disease in non-model species was identified in the retrieved evidence.

15. Model organisms

15.1 Zebrafish (Danio rerio)

Zebrafish rp2 knockout/knockdown models show: - Early photoreceptor functional defects, followed by progressive rod outer segment degeneration and then cone outer segment degeneration (noel2021zebrafishmodelsof pages 10-12) - Disrupted localization/levels of phototransduction proteins (GRK1; rod transducin subunits GNAT1/GNB1) and disrupted farnesylated protein distribution (iribarne2020zebrafishphotoreceptordegeneration pages 6-8)

Model limitation: a review notes that existing animal models may not fully replicate the severe human RP2 phenotype. (pechnikova2025preclinicalandclinical pages 4-6)

Direct quotes from abstracts (available in retrieved evidence)

• XLRP expert panel abstract: “X-linked retinitis pigmentosa (XLRP) is a rare inherited retinal disease manifesting as impaired night vision and peripheral vision loss that progresses to legal blindness… there is currently no approved treatment.” (Birch et al., 2023; DOI:10.1167/tvst.12.6.5) (birch2023overcomingthechallenges pages 1-2)
• Pediatric IRD cohort abstract: “Inherited retinal dystrophies (IRDs) are a common cause of blindness or severe visual impairment in children…” and rod–cone dystrophies include “RP2” among others. (Priglinger et al., 2024; DOI:10.3390/ijms252212259) (priglinger2024phenotypicandgenetic pages 1-2)

Key evidence gaps in this run (important for knowledge base completeness)

1. OMIM/Orphanet/MONDO/ICD identifiers: not present in retrieved sources; should be added from OMIM/Orphanet/MONDO directly in a follow-on extraction. (NCT06982417 chunk 1)
2. RP2 variant catalog (recurrent variants, ACMG classifications, allele frequencies, founder effects): not retrieved; would require ClinVar/gnomAD-focused extraction or RP2-specific variant papers. (pechnikova2025preclinicalandclinical pages 4-6)
3. Female carrier natural history: an RP2 carrier cohort paper (AJO 2024) was listed as unobtainable; carrier penetrance/expressivity therefore cannot be summarized here. (paper search unobtainable list; not citable)
4. RP2-specific patient-reported outcomes/QoL: not retrieved.

References (URLs/DOIs in evidence)

• Birch DG et al. Transl Vis Sci Technol. 2023-06. DOI: https://doi.org/10.1167/tvst.12.6.5 (birch2023overcomingthechallenges pages 1-2)
• Priglinger CS et al. Int J Mol Sci. 2024-11. DOI: https://doi.org/10.3390/ijms252212259 (priglinger2024phenotypicandgenetic pages 10-11)
• Savastano MC et al. Transl Vis Sci Technol. 2024-08. DOI: https://doi.org/10.1167/tvst.13.8.44 (savastano2024retinalpigmentepithelium pages 1-2)
• Areblom M et al. Genes. 2023-07. DOI: https://doi.org/10.3390/genes14071413 (areblom2023adescriptionof pages 1-2)
• Lynn J et al. Genes. 2024-12. DOI: https://doi.org/10.3390/genes16010032 (lynn2024expandingthemutation pages 1-2)
• Pechnikova NA et al. J Clin Med. 2025-01. DOI: https://doi.org/10.3390/jcm14030898 (pechnikova2025preclinicalandclinical pages 4-6)
• Frederick JM et al. Biological Chemistry. 2020-12. DOI: https://doi.org/10.1515/hsz-2019-0375 (frederick2020diffuseorhitch pages 7-10)
• Noel NCL et al. Biomolecules. 2021-01. DOI: https://doi.org/10.3390/biom11010078 (noel2021zebrafishmodelsof pages 10-12)
• Iribarne M. IntechOpen chapter. 2020-09. DOI: https://doi.org/10.5772/intechopen.88758 (iribarne2020zebrafishphotoreceptordegeneration pages 6-8)
• ClinicalTrials.gov: InsightRP2 Registry (NCT06982417). Posted 2025-05-21. https://clinicaltrials.gov/study/NCT06982417 (NCT06982417 chunk 1)
• ClinicalTrials.gov: Vitamin A supplementation in RP (NCT00065455). https://clinicaltrials.gov/study/NCT00065455 (NCT00065455 chunk 1)

References

1. (birch2023overcomingthechallenges pages 1-2): David G. Birch, Janet K. Cheetham, Stephen P. Daiger, Carel Hoyng, Christine Kay, Ian M. MacDonald, Mark E. Pennesi, and Lori S. Sullivan. Overcoming the challenges to clinical development of x-linked retinitis pigmentosa therapies: proceedings of an expert panel. Translational Vision Science & Technology, 12:5, Jun 2023. URL: https://doi.org/10.1167/tvst.12.6.5, doi:10.1167/tvst.12.6.5. This article has 24 citations and is from a peer-reviewed journal.

2. (pechnikova2025preclinicalandclinical pages 4-6): Nadezhda A. Pechnikova, Malamati Poimenidou, Ioannis Iliadis, Maria Zafeiriou-Chatziefraimidou, Aleksandra V. Iaremenko, Tamara V. Yaremenko, Kalliopi Domvri, and Alexey V. Yaremenko. Pre-clinical and clinical advances in gene therapy of x-linked retinitis pigmentosa: hope on the horizon. Journal of Clinical Medicine, 14:898, Jan 2025. URL: https://doi.org/10.3390/jcm14030898, doi:10.3390/jcm14030898. This article has 9 citations.

3. (NCT06982417 chunk 1): Nina Bogershausen. InsightRP2 Registry. University of Göttingen. 2025. ClinicalTrials.gov Identifier: NCT06982417

4. (birch2023overcomingthechallenges pages 2-4): David G. Birch, Janet K. Cheetham, Stephen P. Daiger, Carel Hoyng, Christine Kay, Ian M. MacDonald, Mark E. Pennesi, and Lori S. Sullivan. Overcoming the challenges to clinical development of x-linked retinitis pigmentosa therapies: proceedings of an expert panel. Translational Vision Science & Technology, 12:5, Jun 2023. URL: https://doi.org/10.1167/tvst.12.6.5, doi:10.1167/tvst.12.6.5. This article has 24 citations and is from a peer-reviewed journal.

5. (priglinger2024phenotypicandgenetic pages 10-11): Claudia S. Priglinger, Maximilian J. Gerhardt, Siegfried G. Priglinger, Markus Schaumberger, Teresa M. Neuhann, Hanno J. Bolz, Yasmin Mehraein, and Guenther Rudolph. Phenotypic and genetic spectrum in 309 consecutive pediatric patients with inherited retinal disease. International Journal of Molecular Sciences, 25:12259, Nov 2024. URL: https://doi.org/10.3390/ijms252212259, doi:10.3390/ijms252212259. This article has 5 citations.

6. (priglinger2024phenotypicandgenetic pages 1-2): Claudia S. Priglinger, Maximilian J. Gerhardt, Siegfried G. Priglinger, Markus Schaumberger, Teresa M. Neuhann, Hanno J. Bolz, Yasmin Mehraein, and Guenther Rudolph. Phenotypic and genetic spectrum in 309 consecutive pediatric patients with inherited retinal disease. International Journal of Molecular Sciences, 25:12259, Nov 2024. URL: https://doi.org/10.3390/ijms252212259, doi:10.3390/ijms252212259. This article has 5 citations.

7. (savastano2024retinalpigmentepithelium pages 1-2): Maria Cristina Savastano, Giorgio Placidi, Claudia Fossataro, Federico Giannuzzi, Nicola Claudio D'Onofrio, Lorenzo Hu, Valentina Cestrone, Elena D'Agostino, Ilaria Biagini, Ludovica Paris, Giorgia Coppa, Clara Rizzo, Raphael Kilian, Pietro Chiurazzi, Matteo Bertelli, Paolo Enrico Maltese, Benedetto Falsini, and Stanislao Rizzo. Retinal pigment epithelium and outer retinal atrophy (rora) in retinitis pigmentosa: functional, structural, and genetic evaluation. Translational Vision Science & Technology, 13:44, Aug 2024. URL: https://doi.org/10.1167/tvst.13.8.44, doi:10.1167/tvst.13.8.44. This article has 2 citations and is from a peer-reviewed journal.

8. (areblom2023adescriptionof pages 1-2): Maria Areblom, Sten Kjellström, Sten Andréasson, Anders Öhberg, Lotta Gränse, and Ulrika Kjellström. A description of the yield of genetic reinvestigation in patients with inherited retinal dystrophies and previous inconclusive genetic testing. Genes, 14:1413, Jul 2023. URL: https://doi.org/10.3390/genes14071413, doi:10.3390/genes14071413. This article has 8 citations.

9. (lynn2024expandingthemutation pages 1-2): Jacob Lynn, Samuel J. Huang, Grace K. Trigler, Ronald Kingsley, Razek G. Coussa, and Lea D. Bennett. Expanding the mutation spectrum for inherited retinal diseases. Genes, 16:32, Dec 2024. URL: https://doi.org/10.3390/genes16010032, doi:10.3390/genes16010032. This article has 1 citations.

10. (frederick2020diffuseorhitch pages 7-10): Jeanne M. Frederick, Christin Hanke-Gogokhia, Guoxin Ying, and Wolfgang Baehr. Diffuse or hitch a ride: how photoreceptor lipidated proteins get from here to there. Biological Chemistry, 401:573-584, Dec 2020. URL: https://doi.org/10.1515/hsz-2019-0375, doi:10.1515/hsz-2019-0375. This article has 22 citations and is from a peer-reviewed journal.

11. (frederick2020diffuseorhitch pages 10-13): Jeanne M. Frederick, Christin Hanke-Gogokhia, Guoxin Ying, and Wolfgang Baehr. Diffuse or hitch a ride: how photoreceptor lipidated proteins get from here to there. Biological Chemistry, 401:573-584, Dec 2020. URL: https://doi.org/10.1515/hsz-2019-0375, doi:10.1515/hsz-2019-0375. This article has 22 citations and is from a peer-reviewed journal.

12. (pechnikova2025preclinicalandclinical pages 1-2): Nadezhda A. Pechnikova, Malamati Poimenidou, Ioannis Iliadis, Maria Zafeiriou-Chatziefraimidou, Aleksandra V. Iaremenko, Tamara V. Yaremenko, Kalliopi Domvri, and Alexey V. Yaremenko. Pre-clinical and clinical advances in gene therapy of x-linked retinitis pigmentosa: hope on the horizon. Journal of Clinical Medicine, 14:898, Jan 2025. URL: https://doi.org/10.3390/jcm14030898, doi:10.3390/jcm14030898. This article has 9 citations.

13. (pechnikova2025preclinicalandclinical pages 6-9): Nadezhda A. Pechnikova, Malamati Poimenidou, Ioannis Iliadis, Maria Zafeiriou-Chatziefraimidou, Aleksandra V. Iaremenko, Tamara V. Yaremenko, Kalliopi Domvri, and Alexey V. Yaremenko. Pre-clinical and clinical advances in gene therapy of x-linked retinitis pigmentosa: hope on the horizon. Journal of Clinical Medicine, 14:898, Jan 2025. URL: https://doi.org/10.3390/jcm14030898, doi:10.3390/jcm14030898. This article has 9 citations.

14. (pechnikova2025preclinicalandclinical pages 14-16): Nadezhda A. Pechnikova, Malamati Poimenidou, Ioannis Iliadis, Maria Zafeiriou-Chatziefraimidou, Aleksandra V. Iaremenko, Tamara V. Yaremenko, Kalliopi Domvri, and Alexey V. Yaremenko. Pre-clinical and clinical advances in gene therapy of x-linked retinitis pigmentosa: hope on the horizon. Journal of Clinical Medicine, 14:898, Jan 2025. URL: https://doi.org/10.3390/jcm14030898, doi:10.3390/jcm14030898. This article has 9 citations.

15. (NCT00065455 chunk 1): Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa. National Eye Institute (NEI). 2003. ClinicalTrials.gov Identifier: NCT00065455

16. (noel2021zebrafishmodelsof pages 10-12): Nicole C. L. Noel, Ian M. MacDonald, and W. Ted Allison. Zebrafish models of photoreceptor dysfunction and degeneration. Biomolecules, 11:78, Jan 2021. URL: https://doi.org/10.3390/biom11010078, doi:10.3390/biom11010078. This article has 46 citations.

17. (noel2021zebrafishmodelsof pages 25-27): Nicole C. L. Noel, Ian M. MacDonald, and W. Ted Allison. Zebrafish models of photoreceptor dysfunction and degeneration. Biomolecules, 11:78, Jan 2021. URL: https://doi.org/10.3390/biom11010078, doi:10.3390/biom11010078. This article has 46 citations.

18. (iribarne2020zebrafishphotoreceptordegeneration pages 6-8): Maria Iribarne. Zebrafish photoreceptor degeneration and regeneration research to understand hereditary human blindness. Visual Impairment and Blindness - What We Know and What We Have to Know, Sep 2020. URL: https://doi.org/10.5772/intechopen.88758, doi:10.5772/intechopen.88758. This article has 9 citations.

19. (birch2023overcomingthechallenges pages 6-8): David G. Birch, Janet K. Cheetham, Stephen P. Daiger, Carel Hoyng, Christine Kay, Ian M. MacDonald, Mark E. Pennesi, and Lori S. Sullivan. Overcoming the challenges to clinical development of x-linked retinitis pigmentosa therapies: proceedings of an expert panel. Translational Vision Science & Technology, 12:5, Jun 2023. URL: https://doi.org/10.1167/tvst.12.6.5, doi:10.1167/tvst.12.6.5. This article has 24 citations and is from a peer-reviewed journal.

20. (suleman2025currentunderstandingon pages 5-6): Naning Suleman. Current understanding on retinitis pigmentosa: a literature review. Frontiers in Ophthalmology, Jun 2025. URL: https://doi.org/10.3389/fopht.2025.1600283, doi:10.3389/fopht.2025.1600283. This article has 26 citations.

21. (priglinger2024phenotypicandgenetic pages 16-17): Claudia S. Priglinger, Maximilian J. Gerhardt, Siegfried G. Priglinger, Markus Schaumberger, Teresa M. Neuhann, Hanno J. Bolz, Yasmin Mehraein, and Guenther Rudolph. Phenotypic and genetic spectrum in 309 consecutive pediatric patients with inherited retinal disease. International Journal of Molecular Sciences, 25:12259, Nov 2024. URL: https://doi.org/10.3390/ijms252212259, doi:10.3390/ijms252212259. This article has 5 citations.

Artifacts

• Edison artifact artifact-00